Oppenheimer maintains Zura Bio at Outperform, lowers price target to $5 from $16

Oppenheimer kept Zura Bio's rating at Outperform but cut its price target from $16 to $5, a 68.8% reduction. The new target suggests a 303.2% upside from the Nov 9 close of $1.24, according to the firm.

Original reporting
Published Nov 10, 2026, 4:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Zura Bio at Outperform, lowers price target to $5 from $16 — source image
Decision brief

The 30-second read

$ZURABearishMed
01

Why it matters

Analyst downgrade reflects concerns about near‑term milestones and valuation.

02

Market read

The downgrade may trigger short‑term selling pressure in Zura Bio and influence sentiment in the broader biotech space.

03

What to watch

Potential upcoming trial data or partnership announcements could offset the downgrade.

Relevance 5/10Novelty 5/10Timing: today

Background

Zura Bio is a clinical‑stage biotech focused on oncology therapies.

Company-level read

Ticker impact

$ZURABearishMedium confidence
Context

Oppenheimer lowered Zura Bio's price target to $5 from $16, indicating a significant downgrade.

Expected impact

likely downward pressure as the market prices in the reduced target

Evidence & confidence

The 68.8% target cut signals weaker outlook, prompting potential sell‑offs.

Market effects

May affect sentiment toward other small‑cap biotech stocks.

Limited to U.S. biotech sector.

Low

Counterpoint

Some investors may view the cut as an overreaction and see buying opportunity.

Key entities

  • Zura Bio

    Clinical‑stage biotech firm.

  • Oppenheimer

    Equity research analyst firm issuing the rating change.

Related articles

$ZURAMedAI 8/10

Zura Bio Discontinues Tibulizumab Development In Hidradenitis Suppurativa After Phase 2 Setback

Zura Bio (ZURA) halted development of tibulizumab for hidradenitis suppurativa after its Phase 2 trial failed to meet primary and key secondary goals. Both doses showed similar reductions in abscesses and inflammatory nodules compared to placebo. The company will continue developing the drug for systemic sclerosis and polymyalgia rheumatica. ZURA had $187.7M in cash as of September 30, 2026, and its stock is down 72.24% to $1.13.

$ZURAHighAI 8/10

Why is Zura Bio stock collapsing today?

Zura Bio's stock fell 68.2% after its Phase 2 trial for tibulizumab in hidradenitis suppurativa failed to meet primary and secondary endpoints. The company halted development for this indication, leaving two other trials in its pipeline. Zura Bio has $187.7M in cash, expected to last until 2028, but the market reacted negatively to the setback.